EGFR and adrenal cortex carcinoma: A recent study by Bell et al. is the only study to date to show that the oncogenes KRAS, NRAS and MET are mutated in lacrimal gland ACC, thereby identifying the EGFR–RAS–RAF-signalling pathway as a potential inhibitory target [44].